GlassScriptPhysician profile
Angela C Jones
NPI 1023122900
$1,565.40
in general payments reported to CMS, 2019-2025
28 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $187 · 2021: $206 · 2022: $322 · 2023: $342 · 2024: $69.83 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $521.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $221.06 | 2022-2023 | |
| Pfizer INC. | $200.56 | 2019-2024 | |
| Novo Nordisk INC | $110.78 | 2019-2024 | Wegovy |
| Silk Road Medical, INC. | $103.81 | 2021 | |
| Lilly USA, LLC | $96.17 | 2021-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $83.73 | 2020 | |
| Sunovion Pharmaceuticals INC. | $81.77 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $67.73 | 2019-2020 | |
| Amgen INC. | $66.78 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.71 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.06 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $51.13 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.07 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $48.23 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $46.82 | 2023-2024 | Rexulti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $39.56 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.96 | 2025 | |
| Ironshore Pharmaceuticals INC. | $19.32 | 2019 | |
| Ibsa Pharma INC. | $17.23 | 2022 | |
| Lundbeck LLC | $15.87 | 2023 | Rexulti |
| Gilead Sciences, INC. | $15.76 | 2020 | |
| Merck Sharp & Dohme LLC | $15.05 | 2019 | |
| Supernus Pharmaceuticals, INC. | $15.03 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.29 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $13.27 | 2020 | |
| Avanir Pharmaceuticals, INC. | $13.04 | 2019 | |
| Astellas Pharma US INC | $11.51 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.